Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

NCT06295159 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Melanoma Stage III
Melanoma Stage IV
Advanced Melanoma
Melanoma

Interventions

DRUG: Nivolumab
DRUG: Nivolumab + Relatlimab
DRUG: Ipilimumab

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]